Descrizione del progetto
Migliorare l’efficacia dei nanogel inalabili per il trattamento del carcinoma polmonare
I nanogel sono promettenti sistemi per l’erogazione dei farmaci che risultano in grado di somministrare terapie alle cellule bersaglio nel corpo. Recentemente, queste particelle sono state applicate in modo versatile per il trattamento di vari disturbi e malattie, tra cui il cancro. Sebbene la somministrazione polmonare di terapie mediante nanogel inalabili sia ritenuta vantaggiosa per il trattamento del carcinoma polmonare, è necessario superare diverse sfide affinché sia possibile garantirne un uso diffuso. Il progetto PuDeRegels, finanziato dall’UE, si propone di incrementare l’efficienza dei nanogel in modo da poterli utilizzare per somministrare farmaci antitumorali in modo preciso e sicuro tramite l’apparato respiratorio, fino ai polmoni. Grazie a una combinazione di competenze in materia di scienza dei polimeri e biologia chimica, PuDeRegels si propone di risolvere le sfide legate a problematiche quali incapsulamento del farmaco antitumorale, somministrazione mirata, rilascio del medicinale, biocompatibilità ed evasione dei macrofagi.
Obiettivo
In this project, I will investigate and develop nanogels incorporated into microgels containing encapsulated anticancer drugs. These nanogels will be delivered via the respiratory system to the lung, selectively swell and deliberate the therapeutic. Importance will be given to targeting moieties, stealth moieties, and biocompatibility. The delivery of drugs for lung cancer is limited but is under investigation and on the rise of inquiry. Some of the challenges this type of technology faces are the efficient encapsulation of the bioactive compound inside a nanocarrier, the targeted delivery, the release of the drug, the biocompatibility with the lung, and the avoidance of the macrophages. New methodologies for better delivery of therapeutics are of great importance at the National and International levels. New materials and technologies are emerging every year. The delivery of therapeutics for lung cancer is based mainly on intravenous therapies. Another way of introducing drugs into the area of importance in the lung could be pulmonary drug delivery as a good alternative. Pulmonary delivery is not a new technology but is strictly limited to specific conditions/illnesses. The research capitalizes on the existing strengths of the experienced researcher (ER) in polymer science and the expertise of the host institute in chemical biology in health, drug research, and biotechnology. It will lead to several publications in high-impact factor journals, transfer of knowledge and expertise that could be capitalized at an industrial level, thus contributing to the research output, distinctness, and economy of Europe. Overall, the fellowship will allow the ER to reintegrate into a long-term academic position after many years of fruitful research career in the academic sector in Spain. After this project, the ER will obtain new knowledge and training that will help him to establish a solid point for a better opportunity both in Academy and in Industry.
Campo scientifico
Programma(i)
Argomento(i)
Meccanismo di finanziamento
HORIZON-AG-UN - HORIZON Unit GrantCoordinatore
11635 Athina
Grecia